Sequoia China co-leads $188m round in Covid vaccine developer Stemirna

mRNA driven drugs and vaccines maker Stemirna Therapeutics on Thursday announced that it has raked in 1.2 billion yuan ($188 million) in a new funding round jointly led by Sequoia Capital China, state-backed China Merchants Medical and Healthcare Industry Equity Fund, Chinese global pharma major WuXi AppTec and Greenwoods Investment.